secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-196513
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Q2 net loss $65M; THRIVE topline readout on track for Sept 2024; cash $571.4M
--------------------------------------------------------------------------------

- Net loss of $65.0M in Q2 2024 vs $55.1M Q2 2023; cash balance $571.4M as of June 30, 2024.
- THRIVE phase 3 (active TED) topline data for VRDN-001 expected September 2024.
- THRIVE-2 (chronic TED) enrollment completed with 188 patients, exceeding 159 target; topline due year-end 2024.
- REVEAL-1 and REVEAL-2 phase 3 trials for subcutaneous VRDN-003 to initiate August 2024; topline data H1 2026.
- IND for VRDN-006 (FcRn inhibitor) on track for year-end 2024; NHP data for VRDN-008 expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524196513/0001193125-24-196513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312524196513/d879446d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer